has shown that patients with ‘basal‐like’ (subtype 1) tumours showed a strong trend toward better response to adjuvant therapy when compared to patients from the ‘classical’ (subtype 3) subtype group 6 and that QM‐PDA cell lines were, on average, more sensitive to gemcitabine and less sensitive to erlotinib than the classical cell lines. 6 Additionally, it has been shown that pati
← all excerpts
Immunophenotypes of pancreatic ductal adenocarcinoma: Meta-analysis of transcriptional subtypes.
1
—
—